UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 8, 2006
VERTEX PHARMACEUTICALS INCORPORATED
(Exact name of registrant as specified in its charter)
MASSACHUSETTS | | 000-19319 | | 04-3039129 |
(State or other jurisdiction of
incorporation) | | (Commission File Number) | | (IRS Employer Identification
No.) |
|
130 Waverly Street |
Cambridge, Massachusetts 02139 |
(Address of principal executive offices) (Zip Code) |
|
(617) 444-6100 |
Registrant’s telephone number, including area code: |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On March 8, 2006, Vertex Pharmaceuticals Incorporated issued a press release that reported results from a Phase II clinical study with VX-702, an investigational oral p38 MAP kinase inhibitor, for the treatment of rheumatoid arthritis. A copy of that press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits
Exhibit | | Description of Document |
| | |
99.1 | | Press Release of Vertex Pharmaceuticals Incorporated, dated March 8, 2006, titled “Vertex Reports Investigational p38MAP Kinase Inhibitor, VX-702, Meets Primary Objectives in Phase II Clinical Study in Rheumatoid Arthritis.” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| VERTEX PHARMACEUTICALS
INCORPORATED |
| | (Registrant) |
| |
Date: March 8, 2006 | /s/ Ian F. Smith |
| Ian F. Smith
Executive Vice President and Chief Financial
Officer |
2
